Nattokinase is a fibrinolytic enzyme derived from natto, a traditional Japanese fermented soybean food. Its primary benefits include breaking down fibrin clots in the bloodstream, improving blood flow, reducing blood pressure, supporting cardiovascular health, and potentially reducing the risk of thrombotic events. Clinical research supports its use as a natural complement to cardiovascular health protocols, particularly for adults with elevated clotting risk, high blood pressure, or poor circulatory health.
What Nattokinase Is and Where It Comes From
Nattokinase is produced during the fermentation of soybeans by the bacterium Bacillus subtilis var. natto. It was first identified in 1980 by Japanese researcher Dr. Hiroyuki Sumi, who discovered that natto could dissolve blood clots in a laboratory setting far more effectively than plasmin, the body's own clot-dissolving enzyme, at equivalent concentrations.
Traditional Japanese populations in regions where natto is consumed regularly show lower rates of cardiovascular disease and stroke compared to populations with similar dietary profiles but without natto consumption. While this association cannot be attributed to nattokinase alone, it generated the research interest that produced the controlled clinical studies now available.
What makes nattokinase practically significant is that it is one of the few orally active fibrinolytic compounds. Most enzymes are degraded in the digestive tract and never reach systemic circulation. Nattokinase survives digestion in sufficient quantities to produce measurable fibrinolytic effects in the bloodstream, which is what separates it from many enzyme supplements that are biologically active in a test tube but not in a human body.
How Nattokinase Works in the Body
The cardiovascular system maintains a careful balance between clot formation (coagulation) and clot dissolution (fibrinolysis). When this balance tips toward excessive coagulation, the result is elevated clotting risk, reduced blood flow, and the arterial and venous thrombotic events that cause heart attacks, strokes, and pulmonary embolism.
Nattokinase works by directly degrading fibrin, the protein scaffold that gives blood clots their structural integrity. It also activates the body's own fibrinolytic system by stimulating tissue plasminogen activator (tPA) and inhibiting plasminogen activator inhibitor-1 (PAI-1), which normally suppresses fibrinolysis. This dual mechanism means nattokinase both dissolves existing fibrin deposits and makes the body's clot-clearing machinery more effective.
Additionally, nattokinase inhibits thrombin activity, which reduces the rate at which new fibrin is formed. The combined effect is a meaningful shift in the coagulation-fibrinolysis balance toward improved blood fluidity without the bleeding risk associated with pharmaceutical anticoagulants at standard supplement doses.
The fibrin-inflammation feedback loop in arterial damage explains why addressing both pathways simultaneously produces more comprehensive cardiovascular protection than targeting either one alone.
Clinical Evidence on Blood Pressure
One of the most well-replicated findings in nattokinase research is its effect on blood pressure. A double-blind, randomized controlled trial published in Hypertension Research enrolled 86 hypertensive adults and assigned them to nattokinase at 2,000 FU (fibrinolytic units) per day or placebo for eight weeks. The nattokinase group showed average systolic reductions of 5.55 mmHg and diastolic reductions of 2.84 mmHg compared to placebo.
A follow-up trial in a Korean population produced comparable results, with larger reductions in subjects who had higher baseline blood pressure, suggesting the effect is more pronounced in those who need it most. The proposed mechanism involves nattokinase's ability to reduce renin activity, one of the key enzymatic drivers of the renin-angiotensin-aldosterone system that governs blood pressure regulation.
Stacking nattokinase alongside dietary sodium management, magnesium supplementation, and exercise produces results that significantly exceed any single approach, which is why combining natural interventions for blood pressure control matters more than any single compound acting alone.
Nattokinase and Cardiovascular Disease Risk
Beyond blood pressure, nattokinase addresses several additional cardiovascular risk factors through its fibrinolytic and anti-thrombotic activity.
Fibrin accumulation in arterial walls is a component of atherosclerotic plaque formation. As plaques develop, fibrin provides structural scaffolding that promotes their growth and stability. Nattokinase's ability to degrade fibrin within the arterial wall may slow this process, though the direct evidence in humans remains preliminary compared to the blood pressure data.
Elevated plasma fibrinogen, a clotting protein that predicts cardiovascular risk independently of cholesterol levels, responds to nattokinase supplementation. Studies measuring fibrinogen levels before and after nattokinase use have shown measurable reductions, which translates to reduced overall thrombotic burden in the circulatory system.
Deep vein thrombosis (DVT) risk during prolonged immobility, such as long-haul air travel, is another area where nattokinase is used preventively. Its fibrinolytic activity during periods of venous stasis, when blood pools in the legs due to inactivity, provides a rationale for its use by frequent travelers and people with limited mobility.
The Role of Inflammation in Clotting Risk
Chronic inflammation and coagulation dysfunction are deeply interconnected. Inflammatory cytokines activate the coagulation cascade, and fibrin itself promotes inflammatory signaling. This bidirectional relationship means that people with chronic low-grade inflammation are also at elevated clotting risk, and vice versa.
Nattokinase addresses the fibrin side of this cycle directly. By reducing fibrin accumulation and improving fibrinolytic activity, it also reduces one of the stimuli maintaining chronic inflammatory signaling in vascular tissue. This is why its benefits are most pronounced in adults who have both elevated inflammatory markers and cardiovascular risk factors, rather than in otherwise healthy young adults with neither.
Omega-3 supplementation and nattokinase address complementary aspects of the inflammation-thrombosis interface that drives arterial damage over time, and omega-3s' anti-inflammatory action on vascular tissue is directly relevant to why pairing them produces broader arterial protection.
Nattokinase and Cognitive Circulation
An emerging area of nattokinase research involves cerebral circulation and cognitive health. The brain depends on continuous, uninterrupted blood flow through the smallest capillaries in the body. Any factor that increases blood viscosity, promotes microclot formation, or reduces fibrinolytic activity in cerebral vessels degrades this blood flow and contributes to the cumulative vascular damage that underlies much of age-related cognitive decline.
Nattokinase's fibrinolytic activity applies equally to cerebral vasculature as it does to peripheral and coronary vessels. Some researchers have proposed its use as a preventive intervention for vascular contributions to cognitive impairment, though large-scale human trials specifically targeting cognitive outcomes are limited.
The vascular pathway to age-related cognitive decline is where nattokinase is most logically positioned as a preventive tool, particularly in adults whose cognitive concerns appear alongside identifiable cardiovascular risk factors.
Dosage, Units, and What Labels Actually Mean
Nattokinase is measured in fibrinolytic units (FU), which reflect enzymatic activity rather than simple weight. This distinction matters because two products listing the same milligram weight can have very different levels of biological activity depending on enzyme concentration and purity.
The most commonly studied and clinically referenced dose is 2,000 FU per day, which corresponds to approximately 100 mg of standardized nattokinase extract in most commercial products. Some protocols use 4,000 FU per day for people with more significant cardiovascular risk, though the evidence base at this higher dose is thinner.
Key practical guidance on dosing includes:
- Always use products that state activity in FU rather than only milligrams
- Take nattokinase on an empty stomach, at least 30 to 60 minutes before a meal, to maximize absorption before digestive enzymes alter its activity
- Morning dosing is generally preferred for cardiovascular applications, as clotting risk is highest in the early morning hours when platelet aggregability peaks
- Consistency over weeks and months matters more than any single dose, as fibrinolytic benefits accumulate with sustained use
Nattokinase vs Pharmaceutical Anticoagulants
A common question is how nattokinase compares to pharmaceutical blood thinners such as warfarin, rivaroxaban, or aspirin. The distinction is important to understand clearly.
Pharmaceutical anticoagulants work by blocking specific coagulation factors or platelet activation pathways and carry significant bleeding risks at therapeutic doses. They require monitoring, produce predictable dose-response relationships, and are appropriate for people with diagnosed clotting disorders, atrial fibrillation, prosthetic heart valves, and similar conditions.
Nattokinase works through enzymatic fibrinolysis rather than coagulation factor inhibition. At standard supplement doses, its effect on bleeding time is modest compared to pharmaceutical anticoagulants, and it has not produced significant bleeding events in clinical trials. However, it does have meaningful fibrinolytic activity and should not be combined with anticoagulant or antiplatelet medications without medical supervision, as additive effects on bleeding risk are possible.
Nattokinase is best understood as a natural cardiovascular support compound that works within a broader health protocol, not a pharmaceutical substitute, and building long-term cardiovascular resilience through lifestyle and nutrition reflects the correct framing for using it effectively.
Stacking Nattokinase With Other Cardiovascular Compounds
Nattokinase integrates well with other cardiovascular support compounds because its mechanism is distinct from most others in this category. It addresses the fibrinolysis side of the coagulation-fibrinolysis balance, while most cardiovascular supplements target inflammation, lipids, blood pressure, or mitochondrial energy production.
Combining it with compounds that address these other pathways produces more comprehensive cardiovascular protection than any single agent provides alone.
- CoQ10: Addresses cardiac mitochondrial energy production and endothelial oxidative stress. Complementary rather than overlapping with nattokinase's fibrinolytic mechanism.
- Omega-3 fatty acids: Reduce platelet aggregation, lower triglycerides, and reduce arterial inflammation. Their antiplatelet activity partially overlaps with nattokinase's antithrombotic effects, which is worth noting for people already taking both.
- Magnesium: Reduces vascular smooth muscle tone and buffers the cortisol response that promotes platelet activation under stress. Magnesium's role in vascular relaxation and cardiovascular risk explains the mechanism in the context of both physical and cardiovascular health.
- Berberine: Addresses insulin resistance, lipid metabolism, and vascular inflammation. Berberine's metabolic pathways in arterial disease covers how these interventions target the metabolic drivers of arterial disease that fibrinolysis alone cannot address.
Serrapeptase vs Nattokinase
Serrapeptase is another enzyme supplement frequently discussed alongside nattokinase. Both are proteolytic enzymes with fibrinolytic activity, but their properties and evidence bases differ in ways that matter practically.
Serrapeptase is derived from bacteria found in silkworms and has broader proteolytic activity, degrading multiple protein substrates beyond fibrin. It is used primarily for its anti-inflammatory effects, reducing swelling and protein-based inflammatory debris in tissue. Its cardiovascular fibrinolytic evidence is weaker than nattokinase's.
Nattokinase is more specific for fibrin and has the stronger clinical evidence for blood pressure reduction and systemic fibrinolysis. For cardiovascular applications, nattokinase is the more supported choice. For inflammatory conditions involving tissue repair, serrapeptase is more commonly used. Some practitioners combine both for people managing both cardiovascular and inflammatory conditions simultaneously, though robust combination trial data is limited.
Who Should Consider Nattokinase
Nattokinase is not necessary for everyone, and the benefit is most pronounced in specific populations with identifiable cardiovascular risk factors.
Adults most likely to see meaningful benefit include:
- People with elevated cardiovascular risk factors including hypertension, high fibrinogen, insulin resistance, or family history of clotting events
- Frequent long-haul travelers who need preventive support for deep vein thrombosis risk during extended immobility
- Adults with sedentary lifestyles or occupations that involve prolonged sitting, which reduces venous blood return and increases lower-limb clotting risk
- People seeking to reduce cardiovascular risk who are not candidates for or choose not to use pharmaceutical anticoagulants
- Adults over 50 whose natural fibrinolytic capacity has declined alongside other age-related cardiovascular changes
Managing age-related cardiovascular risk proactively frames this population-level risk in terms of prevention rather than reactive treatment after events occur.
Safety, Contraindications, and Medical Supervision
Nattokinase has a favorable safety profile in clinical trials at standard doses of 2,000 to 4,000 FU per day. No significant adverse effects have been reported in well-conducted trials of up to six months duration. However, several important safety considerations apply.
People taking anticoagulant or antiplatelet medications including warfarin, heparin, aspirin, clopidogrel, or newer oral anticoagulants should not add nattokinase without direct medical supervision. The additive fibrinolytic effect creates bleeding risk that is difficult to predict without monitoring.
People with bleeding disorders, those scheduled for surgery within two weeks, and pregnant women should avoid nattokinase supplementation. Anyone who has had a recent stroke should also consult a physician before use, as the appropriate management of post-stroke coagulation status varies significantly by individual circumstance.
Frequently Asked Questions
What is nattokinase used for
Nattokinase is used primarily as a natural cardiovascular support supplement. Its main applications are improving blood fluidity by breaking down fibrin clots, reducing blood pressure, lowering elevated fibrinogen levels, and supporting overall circulatory health. It is also used preventively for deep vein thrombosis risk during prolonged immobility and as part of broader cardiovascular health protocols in adults with multiple risk factors.
How long does nattokinase take to work
Nattokinase produces measurable fibrinolytic activity in the bloodstream within hours of a single dose, based on studies measuring plasma fibrinolytic markers. However, the clinically meaningful benefits reported in trials, including blood pressure reductions and fibrinogen lowering, typically develop over four to eight weeks of consistent daily use. Like most cardiovascular interventions, its benefits are cumulative and depend on sustained supplementation rather than short-term use.
Is nattokinase safe to take daily
Clinical trials using nattokinase at 2,000 FU per day for up to six months have not reported significant adverse effects in healthy adults not taking blood-thinning medications. Daily use at this dose is considered appropriate for cardiovascular support. People taking anticoagulant or antiplatelet medications, those with bleeding disorders, and those approaching surgery should not take nattokinase without medical clearance due to additive bleeding risk.
Can nattokinase replace blood thinners
No. Nattokinase is a fibrinolytic supplement with a mild to moderate effect on blood fluidity at supplement doses. It does not replicate the predictable, titrated anticoagulant effects of pharmaceutical blood thinners and is not appropriate for people with conditions that require reliable anticoagulation, such as atrial fibrillation with high stroke risk, prosthetic heart valves, or prior venous thromboembolism. It may be used as a preventive tool in lower-risk adults but should never substitute for prescribed anticoagulant therapy.
What is the best dose of nattokinase for cardiovascular health
The most studied dose is 2,000 FU per day, which is the amount used in the most cited randomized controlled trials showing blood pressure reduction and fibrinolytic effects. Some protocols use 4,000 FU per day for people with elevated clotting risk, though the evidence at higher doses is less extensive. Products should always list activity in fibrinolytic units rather than only milligrams to allow meaningful dosage comparison between brands.
Does nattokinase interact with any medications
Yes. Nattokinase has meaningful interactions with anticoagulant and antiplatelet medications including warfarin, heparin, aspirin, clopidogrel, and newer oral anticoagulants such as rivaroxaban and apixaban. The additive effect on fibrinolysis and platelet activity increases bleeding risk in a way that is difficult to manage without medical monitoring. It may also interact with medications that affect blood pressure. Anyone on prescription cardiovascular medications should consult their physician before adding nattokinase.
What is the difference between nattokinase and serrapeptase
Both are proteolytic enzyme supplements with fibrinolytic properties, but they differ in specificity and evidence base. Nattokinase is more specific for fibrin degradation and has stronger clinical evidence for blood pressure reduction and systemic fibrinolysis. Serrapeptase has broader proteolytic activity and is used more commonly for its anti-inflammatory effects in tissue repair contexts. For cardiovascular fibrinolysis specifically, nattokinase has the more robust evidence base. Some practitioners combine both when addressing both cardiovascular and inflammatory concerns simultaneously.
Â